Study objective: To determine the feasibility, toxicity, and potential efficacy of neoadjuvant chemoradiotherapy before surgery in patients with non-small cell lung cancer limited to the chest. Design: Phase 2 pilot study. Setting: Multi-institutional, multimodality cooperative group. Patients: Eight-five patients with advanced stage III-A or minimal stage III-B non-small cell lung cancer in whom attempted resection would have been likely to leave residual disease.
Intervention: Cisplatin, 75 mg/m2, was given on days 1 and 29; fluorouracil, 1 g/m2 for 24 h, was given as a continuous infusion on days 1 involvement was encouraged, but CT documentation (single node >2 cm or multiple nodes >1.5 cm) was permitted. According to the revised TNM staging system,2 which was introduced after the initiation of this protocol, these criteria defined patients with relatively advanced stage Ill-A or minimal stage Ill-B disease. The protocol therapy is depicted in Figure 1 . Details of patient inclusion and exclusion criteria, chemotherapy administration and radiation therapy technique, and quality assurance have been detailed previously.' All institutional, National Cancer Institute, and federal regulations regarding informed consent and peer review were fulfilled. Standard response and toxicity criteria and statistical methods were employed. Patients who underwent thoracotomy were grouped as follows: (1) those with complete resection, ie, resection of all tumor with histologically free margins; (2) those with incomplete resection, ie, resection possible but grossly evident tumor remaining or margins of resection positive for tumor or tumor in the highest resected lymph nodes; and (3) those with unresectable disease. The major objectives were as follows: (1) (Fig 2) . Thirteen patients died without tumor recurrence: 3 during chemoradiotherapy or before surgery, 4 because of postoperative complications, and 6 because of miscellaneous cardiac or pulmonary problems. Survival within the most favorable subset of patients, ie, those eight patients found to have no viable tumor at surgery, was as follows: one, alive and without disease at 38 months after initiation of therapy; one, alive at 30 months after treatment of a second primary tumor; one died with postoperative complications; and five died of recurrent tumor. These results indicate, however, that neoadjuvant chemoradiotherapy altered the usual patterns of disease recurrence observed in patients with locally advanced non-small cell lung cancer. Patients whose tumors were completely resected were less likely to have recurrences initially only locally (17% vs 46%) and were more likely to have recurrences in the brain (17% vs 5%) than were patients whose tumors could not be completely resected. These results emphasize that the relative effectiveness of the local therapy, even after preoperative chemoradiotherapy, depends on the completeness of the resection. The likelihood of local tumor recurrence in patients with incomplete tumor resection poses the possibility of benefit from higher doses of radiotherapy in an optimal neoadjuvant regimen, while the high likelihood of systemic relapse in patients with complete resection highlights the need for more effective chemotherapy than that used in this study.
We have previously reported the relatively low incidence (6.8%) of first recurrences involving the brain after complete surgical resection of stage I to III non-small cell lung cancer and concluded that prophylactic cranial radiation would at best benefit only a very small proportion of these patients.3 Although the number of patients in this study is small, our results suggest that the likelihood of disease recurrence of the brain of patients whose tumors were completely resected after neoadjuvant chemoradiotherapy is high enough that these patients might benefit from prophylactic cranial irradiation. Alternatively, this group may provide an appropriate subset of all patients with non-small cell lung cancer in which to study the efficacy of prophylactic cranial irradiation.
Other investigators have also explored the utility of neoadjuvant therapy in patients with locally advanced non-small cell lung cancer. These results, most of which have been reported subsequent to the initiation and patient accrual to the trial described in this report, were discussed at this meeting by Dr. Penfield Faber and have been also reviewed elsewhere.4'5 All investigators of neoadjuvant therapy have experienced difficulty in defining the extent of disease at the initiation of therapy, ie, defining both the methodology by which tumor extent is determined and defining which subsets of patients with locally advanced non-small cell lung cancer are appropriate candidates for neoadjuvant therapy. In the study described herein, the criterion employed was "technically unresectable disease which would likely result in gross residual disease," an admittedly somewhat subjective criterion. Pathologic staging of mediastinal nodes, eg, by mediastinoscopy, was not a requirement for study entry. Most investigators today, however, would insist on pathologic staging of the mediastinum prior to institution of neoadjuvant therapy. In addition, in the study reported herein, 13% of the patients had stage Ill-B disease. Today, most, but not all, investigators would consider patients with stage Ill-B tumors categorically to have unresectable disease and thus not be eligible for studies of neoadjuvant therapy.
Ultimately, the determination of whether patients with stage III-A disease benefit from neoadjuvant therapy followed by surgery will require data from randomized trials. The trial reported herein, a phase 2 pilot study of concurrent cisplatin and fluorouracil chemotherapy and radiation therapy before surgery, was one of several phase 2 trials that provided the clinical background and impetus for the initiation of more definitive phase 3 trials, the results of which are eagerly awaited.
